Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8

Jerusalem, G.Prat, A.Salgado, R. F.Reinisch, M.Saura, C.Ruiz Borrego, M.Nikolinakos, P.Filian, J.Ades, F.Huang, N.Mazzei-Abba, A.Tolaney, S. M.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21901enNeoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8conference outputopen access10.1016/j.annonc.2022.03.1081569-8041http://www.annalsofoncology.org/article/S0923753422004872/pdf792494100094